Quadruplet Therapy and Treatment Individualization in Newly Diagnosed Multiple Myeloma

Dr. Hans Lee, Dr. Prashant Kapoor, and Dr. Muhamed Baljevic discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, including its use across transplant-eligible and transplant-ineligible populations. The panel reviews how emerging data from studies such as PERSEUS, CEPHEUS, and MIDAS are influencing treatment selection and the role of autologous stem cell transplantation. Dr. Kapoor highlights the potential to defer transplantation in selected patients who achieve deep MRD-negative responses with induction therapy, while emphasizing that treatment should remain individualized based on patient fitness and ability to tolerate intensive regimens. The discussion also addresses when a triplet regimen may be more appropriate, particularly for frailer patients, with anti-CD38 antibody-based combinations offering an alternative approach. The experts consider ongoing studies evaluating treatment intensification and the role of a fourth agent, including EQUATE, and how these data may further refine treatment duration, regimen selection, and personalized management in newly diagnosed multiple myeloma.